<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="926">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00695019</url>
  </required_header>
  <id_info>
    <org_study_id>07HWHC09</org_study_id>
    <nct_id>NCT00695019</nct_id>
  </id_info>
  <brief_title>Interferon-alpha Lozenges for Prevention of Relapse in Hepatitis C</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Low-Dose Human Interferon-alpha by the Oral Mucosal Route During the 6-Month Follow-up Period of Standard Combination Therapy for Hepatitis C Virus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amarillo Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CytoPharm, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Amarillo Biosciences, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Taiwan: Department of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether lozenges of interferon-alpha that are
      dissolved in the mouth can prevent relapse in patients with hepatitis C virus infection who
      had a complete virologic response after receiving a combination of injected interferon-alpha
      and oral ribavirin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Relapse Rate</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of participants with a positive seum HCV RNA level at any post-baseline evaluation
Serum HCV RNA was tested using a commercially available real-time polymerase-chain-reaction (PCR) assay kit (Roche Cobas TaqMan HCV assay kit) with a limit of detection of 15 IU/ml.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sustained Virologic Response Rate</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of participants who remained HCV RNA negative throughout the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalization of ALT</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of participants with a normal serum ALT level at the end of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum HCV RNA Concentration</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in serum HCV RNA concentration (log10 IU) from baseline to week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum ALT</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in Serum ALT concentration from baseline to week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Social Functioning</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in the Social Functioning domain of the SF-36 quality-of-life questionnaire from baseline to week 48
Social Functioning (SF) scores range from 0-100, with lower scores indicating that health/emotional problems have had a greater negative impact on social activities, compared to higher scores. SF scores are calculated using a proprietary algorithm based on responses to questions #6 and #10 on the SF-36, which are 5-point likert scales about the extent to which, and the amount of time with which physical or emotional problems have interfered with social activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fibrotest Score</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in fibrotest score from baseline to week 48</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">169</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>500 IU qd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 IU Interferon-alpha lozenge taken once per day plus 2 placebo lozenges per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>500 IU tid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 IU interferon-alpha lozenge taken 3 times per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo lozenges taken 3 times per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>interferon-alpha lozenges</intervention_name>
    <description>500 IU lozenges of natural human interferon-alpha for oral dissolution given once or three times per day for 24 weeks</description>
    <arm_group_label>500 IU qd</arm_group_label>
    <arm_group_label>500 IU tid</arm_group_label>
    <other_name>IFN-alpha</other_name>
    <other_name>Veldona lozenges</other_name>
    <other_name>oral interferon</other_name>
    <other_name>IFN-alpha lozenges</other_name>
    <other_name>oral interferon lozenges</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo lozenges</intervention_name>
    <description>200 mg matching placebo lozenges</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>sugar pills</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HCV genotype 1b

          -  Will be completing pegylated IFN-alpha and ribavirin therapy within 4 weeks

          -  Serum HCV RNA negative within 4 weeks of study entry

        Exclusion Criteria:

          -  Child-Pugh score of B or C

          -  Decompensated liver function

          -  History of malignancy within past 5 years

          -  Other causes of liver disease besides HCV infection

          -  Uncontrolled diabetes or hypertension

          -  Unwilling to use two forms of birth control during study treatment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dalin Buddhist Tzu Chi General Hospital</name>
      <address>
        <city>Dalin</city>
        <state>Chiayi County</state>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Chang Gung Memorial Hospital</name>
      <address>
        <city>Niaosong</city>
        <state>Kaosiung County</state>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Show-Chwan Memorial Hospital</name>
      <address>
        <city>Changhua</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chia-Yi Chang Gung Memorial Hospital</name>
      <address>
        <city>Chia-Yi</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiayi Christian Hospital</name>
      <address>
        <city>Chiayi</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keelung Chang Gung Memorial Hospital</name>
      <address>
        <city>Keelung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>105</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 27, 2013</lastchanged_date>
  <firstreceived_date>June 9, 2008</firstreceived_date>
  <firstreceived_results_date>February 5, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prevention of Relapse</keyword>
  <keyword>HCV genotype 1b</keyword>
  <keyword>Recurrence</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferons</mesh_term>
  </intervention_browse>
  <!-- Results are available for this study                                           -->
</clinical_study>
